MBTA Orange Line Service Suspended, Green Line Closed From Government Center to Union Square Station Through 9/18. Learn more at somervillema.gov/MBTAclosure 311 311 Event | Pursuant to Chapter 107 of the Acts of 2022, this public meeting will be conducted via remote participation. Join Zoom Meeting https://us06web.zoom.us/j/81229684302?pwd=eE5KdGJYR214OS9HNFlzaHVGNHNIU… Meeting ID: 812 2968 4302 Passcode: 001238 One tap mobile +16465588656,,81229684302# US (New York) +16469313860,,81229684302# US Dial by your location +1 646 558 8656 US (New York) +1 646 931 3860 US +1 301 715 8592 US (Washington DC) +1 309 205 3325 US +1 312 626 6799 US (Chicago) +1 564 217 2000 US +1 669 444 9171 US +1 719 359 4580 US +1 720 707 2699 US (Denver) +1 253 215 8782 US (Tacoma) +1 346 248 7799 US (Houston) +1 386 347 5053 US Meeting ID: 812 2968 4302 Find your local number: https://us06web.zoom.us/u/kdBaaWOS7h FREE Need special assistance? Request accommodations A Good Way to start the Day! This is a class for all levels. ✓ Easy-to-follow program lets you stretch and relax. ✓ It’s an invigorating, community-oriented yoga class that… Six Games Lunch available after Bingo
Our popular men’s group meets the second Tuesday of the month. New and returning members are welcome. Please submit website feedback using this form. Be sure to include:
TORONTO — Marsha Hunt, one of the last surviving actors from Hollywood’s so-called Golden Age of the 1930s and 1940s who worked with performers ranging from Laurence Olivier to Andy Griffith in a career disrupted for a time by the McCarthy-era blacklist, has died. She was 104. Hunt, who appeared in more than 100 movies and TV shows, died Wednesday at her home in Sherman Oaks, California, said Roger Memos, the writer-director of the 2015 documentary “Marsha Hunt’s Sweet Adversity.” A Chicago native, she arrived in Hollywood in 1935 and over the next 15 years appeared in dozens of films, from the Preston Sturges comedy “Easy Living” to the adaptation of Jane Austen’s “Pride and Prejudice” that starred Olivier and Greer Garson. She was well under 40 when MGM named her “Hollywood’s Youngest Character Actress.” And by the early 1950s, she was enough of a star to appear on the cover of Life magazine and seem set to thrive in the new medium of television when suddenly “the work dried up,” she recalled in 1996.
The reason, she learned from her agent, was that the communist-hunting Red Channels publication had revealed that she attended a peace conference in Stockholm and other supposedly suspicious gatherings. Alongside Hollywood stars Lauren Bacall, Humphrey Bogart and Danny Kaye, Hunt also went to Washington in 1947 to protest the House Un-American Activities Committee, which was conducting a witch hunt for communists in the film industry. “I’d made 54 movies in my first 16 years in Hollywood,” Hunt said in 1996. “In the last 45 years, I’ve made eight. That shows what a blacklist can do to a career.” Hunt concentrated on the theater, where the blacklist was not observed, until she began occasionally getting film work again in the late 1950s. She appeared in the touring companies of “The Cocktail Party,” “The Lady’s Not for Burning” and “The Tunnel of Love,” and on Broadway in “The Devil’s Disciple,” “Legend of Sarah″ and “The Paisley Convertible.” Marcia Virginia Hunt (she changed the spelling of her first name later) was born in Chicago and grew up in New York City, daughter of a lawyer-insurance executive and a voice teacher. Slender and stylish, with a warm smile and large, expressive eyes, Hunt studied drama and worked as a model before making her film debut. An early marriage to director Jerry Hopper ended in divorce. In 1948 she married film writer Robert Presnell Jr., and they had one daughter, who died soon after her premature birth. Her husband died in 1986. Hunt’s first movie was 1935′s “The Virginia Judge.” She went on to play demure roles in a series of films for Paramount, including “The Accusing Finger” and “Come on Leathernecks,” but, as she told The Associated Press in 2020, she was tired of “sweet young things” and begged for more substantial work.
Hollywood proved a painful education. In “Marsha Hunt’s Sweet Adversity,” she remembered almost getting the part of Melanie Wilkes in “Gone with the Wind,” even being assured by producer David O. Selznick. Within days, Olivia de Havilland was announced as the actor who would play Melanie for the 1939 epic. “That’s the day I grew up,” Hunt said in the documentary. “That’s the day I knew I could never have my heart broken again by this profession of acting.” She left Paramount for MGM around the time of “Gone with the Wind” and had lead or supporting roles in “These Glamour Girls,” “Flight Command” and “The Human Comedy” among other movies. “MGM was sheer magic,” she recalled in a 2007 Associated Press interview. “When I arrived at the studio for a one-day role, they parked my car. I went on the set and found a director’s chair with a sign on it, ‘Miss Hunt.’ Another sign was on my dressing room. “I said to myself, ‘Any studio that treats a one-day player that way, really knows how to make pictures.’ They won my loyalty.” Work unraveled quickly after she openly embraced liberal causes, such as joining the 1947 protest against congressional hearings on the reputed communist influence in Hollywood. “I was never a communist or even interested in the communist cause,” she declared in 1996. “I was a political innocent defending my industry.” With a couple of exceptions, such as producer Stanley Kramer’s 1952 family comedy “The Happy Time,” she was unseen on the big screen for most of the 1950s. She later appeared in many TV series, including “My Three Sons,” “Matlock,” “All in the Family” and “Murder, She Wrote.” She remained vigorous and elegant in old age. In 1993, she put out “The Way We Wore: Styles of the 1930s and ’40s and Our World Since Then,” a lavishly illustrated book of the fashions during her Hollywood heyday. A lifelong political activist, Hunt had a brush with terror in 1962 when she took part in a forum on right-wing extremists and two other participants’ homes were damaged by homemade bombs the very same evening. “The ashen-faced actress said her home probably escaped the bomb attack only because the terrorists were unable to find out where she lived,” the Los Angeles Times reported. Police were sent to guard her home. More recently, she helped create a refuge for the homeless in Los Angeles’ Sherman Oaks neighborhood, where she lived and was feted with the title honorary mayor. Looking back on her activist years, Hunt remarked in 1996: “I never craved an identity as a figure of controversy. But having weathered it and found other interests in the meantime, I can look back with some philosophy.” Copyright 2022 NPR. To see more, visit https://www.npr.org.
MERIDEN — When he fell in love with music at age 11, Ángel Hernández did not know his passion would help him fulfill his needs as an adult who lives with a chronic condition.
Hernández, whose artistic name is Taylor on the Beat, was diagnosed with polycystic kidney disease when he was 18 month old. Despite the challenges, and the fact that he can lift no more than five pounds due to the condition, the Dominican father has been able to work from home creating music, collaborating with different artists and generating an income.
The Meriden resident produces different audio materials from his home based studio equipped with acoustic panels, compressors and musical instruments. His services incorporate music beats, song lyrics, voice quality adjustment, equalization, masterization and effects, depending on his client’s needs. He also works on commercials and is represented by Apocalypsis Music Group.
A passion for music
At age 11, while living in the Dominican Republic, Hernández visited the home of his friend Jorge “CJ” Tonos to play video games. The piano at CJ’s home caught his attention to the point that eventually he learned the instrument and he and CJ started composing music, said Hernández, who also learned audio software from his friend.
Later, when he was 17 years old, Hernández began purchasing equipment and instruments, and created a customer base producing music. He and Tonos have collaborated on many projects and plan on continuing to do so.
Michael Febles Quezada, known as Michael Sunshine, is a producer that taught Hernández guitar, sound selection, choosing music elements that fit voice types and piano chords, he said. The producer also has connections in the music industry, including American reggaeton singer Arcángel. Hernández was introduced to many artists by Quezada.
Working in the U.S.
In 2017, Hernández moved to the U.S. and took a break from music. Three years ago, he started from scratch, creating his home studio and connecting with more musical talent in the U.S., he said. Starting over was challenging as being physically present is important in the music industry. However, that didn’t stop him and his current client base is not local.
He has clients in Boston, Virginia, Miami and New York and noted he sometimes travels to meet artists. Other times, the collaboration happens from his home studio.
When Hernández travels for work, he does it for a limited amount of time due to the equipment he brings for his dialysis treatments. He hopes to get a kidney transplant in three years, when he can become an American citizen and therefore qualify for a health insurance that would cover the transplant.
A recent success
Guillermo “Polo” Parra, a sound engineer who also works with prominent artists, opened many doors for Hernández, he said. Thanks to Parra, Hernández recently worked on 17 songs for Pina Records, a Puerto Rican record label founded by Rafael Antonio Pina Nieves. Pina Records manages Natti Natasha, Daddy Yankee, Plan B and R.K.M & Ken-Y.
Hernández noted another success was an album he helped create for El Philippe, which in 2019 won best production in “Premios El Galardón,” an award ceremony that recognizes Christian music in Spanish.
“I am where I have always wanted to be,” he said regarding his career.
“Seeing the change from where he started to what he is now really makes me proud to be a part of the growth he has had,” said Tonos, who lives in the Dominican Republic.
MERIDEN — When he fell in love with music at age 11, Ángel Hernández did not know his passion would help him fulfill his needs as an adult who lives with a chronic condition. Hernández, whose artistic name is Taylor on the Beat, was diagnosed with polycystic kidney disease when he was 18 month old. Despite the challenges, and the fact that he can lift no more than five pounds due to the condition, the Dominican father has been able to work from home creating music, collaborating with different artists and generating an income. The Meriden resident produces different audio materials from his home based studio equipped with acoustic panels, compressors and musical instruments. His services incorporate music beats, song lyrics, voice quality adjustment, equalization, masterization and effects, depending on his client’s needs. He also works on commercials and is represented by Apocalypsis Music Group. At age 11, while living in the Dominican Republic, Hernández visited the home of his friend Jorge “CJ” Tonos to play video games. The piano at CJ’s home caught his attention to the point that eventually he learned the instrument and he and CJ started composing music, said Hernández, who also learned audio software from his friend. Later, when he was 17 years old, Hernández began purchasing equipment and instruments, and created a customer base producing music. He and Tonos have collaborated on many projects and plan on continuing to do so. Michael Febles Quezada, known as Michael Sunshine, is a producer that taught Hernández guitar, sound selection, choosing music elements that fit voice types and piano chords, he said. The producer also has connections in the music industry, including American reggaeton singer Arcángel. Hernández was introduced to many artists by Quezada. In 2017, Hernández moved to the U.S. and took a break from music. Three years ago, he started from scratch, creating his home studio and connecting with more musical talent in the U.S., he said. Starting over was challenging as being physically present is important in the music industry. However, that didn’t stop him and his current client base is not local. He has clients in Boston, Virginia, Miami and New York and noted he sometimes travels to meet artists. Other times, the collaboration happens from his home studio. When Hernández travels for work, he does it for a limited amount of time due to the equipment he brings for his dialysis treatments. He hopes to get a kidney transplant in three years, when he can become an American citizen and therefore qualify for a health insurance that would cover the transplant. Guillermo “Polo” Parra, a sound engineer who also works with prominent artists, opened many doors for Hernández, he said. Thanks to Parra, Hernández recently worked on 17 songs for Pina Records, a Puerto Rican record label founded by Rafael Antonio Pina Nieves. Pina Records manages Natti Natasha, Daddy Yankee, Plan B and R.K.M & Ken-Y. Hernández noted another success was an album he helped create for El Philippe, which in 2019 won best production in “Premios El Galardón,” an award ceremony that recognizes Christian music in Spanish. “I am where I have always wanted to be,” he said regarding his career. “Seeing the change from where he started to what he is now really makes me proud to be a part of the growth he has had,” said Tonos, who lives in the Dominican Republic. [email protected]: @KarlaSantosNews
Conferences | ESMO Congress A quality-of-life analysis of the pivotal Destiny-Breast04 trial showed that trastuzumab deruxtecan outperformed physician’s choice of treatment in delaying definitive deterioration. An analysis of patient-reported outcomes (PROs) suggests that patients who receive fam-trastuzumab deruxtecan-nxki (Enhertu) maintain quality of life (QOL), with longer time to deterioration and manageable nausea, vomiting, and fatigue, compared with patients who receive physician’s choice of treatment (TPC), in the DESTINY-Breast04 trial (NCT03734029). The findings show that the recently approved antibody-drug conjugate offers a viable safety profile for patients with hormone receptor–positive, HER2-low metastatic breast cancer.
“Overall, global health scores [GHS] and QOL in DESTINY-[Breast]04 was maintained for patients in the hormone receptor–positive cohort during the entire treatment period of trastuzumab deruxtecan [8.2 months] and TPC [3.5 months],” Ueno, who is the section chief of Translation Breast Cancer Research, and the Nylene Eckles Distinguished Professor in Breast Cancer, in the Department of Breast Medical Oncology at The University of Texas MD Anderson said in a presentation of the findings during the 2022 European Society of Medical Oncology Annual Meeting.
“The mean change from [baseline] remained stable with trastuzumab deruxtecan up to 27 cycles and with TPC up to 13 cycles,” added Ueno, who is also the executive director of The University of Texas MD Anderson Cancer Center Morgan Welch Inflammatory Breast Cancer Research Program and Clinic.
Time to definitive deterioration (TDD) was similar between the 2 arms among all PRO measures of interest. Specifically, the TDD in GHS and QOL between the experimental and control arms was 11.4 months (95% CI, 8.8-16.3) and 7.5 months (95% CI, 5.9%-9.5%), respectively, with a hazard ratio of 0.69 (95% CI, 0.52-0.92; P = .0096). Pain symptoms were stable with trastuzumab deruxtecan as well, with a median TDD of 16.4 months (95% CI, 13.1-21.5), compared with 6.1 months (95% CI, 4.2-75 months) with TPC (HR, 0.40; 95% CI, 0.3-0.54; P < .0001).
Patients also reported superior physical, emotional, and social functioning scores with trastuzumab deruxtecan compared with TPC, according to responses collected via the European Organization for Research and Treatment of Cancer Quality of Life Core 30 questionnaire (EORTC QLQ-C30). The TDD for physical function was 16.6 months vs 7.5 months, respectively, (HR, 0.53; 95% CI, 0.40-0.70; P < .001); 19.2 months vs 10.5 months for emotional function (HR, 0.69; 95% CI, 0.50-0.96; P = .0266); and 12.8 months vs 6.0 months for social functioning (HR, 0.59; 95% CI, 0.45-0.77; P = .001).
With both drugs, the fatigue scores remained stable for the duration of data collection, investigators noted, with a TDD of 11.1 months vs 4.5 months between the 2 arms, respectively (HR, 0.61; 95% CI, 0.47-0.79; P = .0002), The PRO collection revealed that nausea and vomiting were worse with trastuzumab deruxtecan compared with TPC; however, this increase was only clinically relevant for the first 6 cycles. For cycles 7 through 27, nausea and vomiting scores decreased and remained within 10 points of baseline. The TDD for nausea and vomiting was 5.7 months vs 9.3 months (HR, 1.46; 95% CI, 1.09-1.96; P = .0128).
Ultimately, the changes from baseline in fatigue symptoms were similar between the 2 arms and did not worsen overtime with trastuzumab deruxtecan. Although patients did experience more initial nausea and vomiting with the antibody drug conjugate, these symptoms decreased and stabilized by cycle 7.
Moreover, findings from the breast cancer-specific EORTC QLQ-BR23 assessment showed that trastuzumab deruxtecan helped delay deterioration from breast-specific symptoms. The TDD for arm symptoms was 14.4 months vs 8.7 months (HR, 0.62; 95% CI, 0.45-0.85; P = .0027). Breast symptom TDD was not estimable in either arm (HR, 0.71; 95% CI, 0.50-1.01; P = .1008). However, an analysis of breast specific symptoms showed that patients receiving trastuzumab deruxtecan had a TDD of systemic therapy adverse effects of 13.6 months (95% CI, 8.3-22.3) vs 6.1 months (95% CI, 4.4-7.7) with TPC. The hazard ratio in this analysis was 0.70 (95% CI, 0.53-0.92; P = .0110).
Additionally, findings from the EuroQol 5-dimension scale questionnaire (EQ-5D-5L) demonstrated that TDD in the visual analog scale was 12.0 months with trastuzumab vs 6.8 with TPC months in DESTINY-Breast04 (HR, 0.73; 95% CI, 0.54-0.97; P = .0288).
The open-label, multicenter, phase 3 DESTINY-Breast04 was designed to compare trastuzumab deruxtecan against TPC in patients with hormone receptor–positive, HER2-low metastatic breast cancer. Eligible patients were pretreated and refractory to endocrine therapy. Patients needed to have received 1 to 2 prior lines of chemotherapy to qualify for enrollment. Enrolled patients were randomly assigned 2:1 to receive either trastuzumab deruxtecan at the recommended dose of 5.4 mg/kg every 3 weeks, or TPC (capecitabine, eribulin, gemcitabine, paclitaxel, or nab-paclitaxel).
This was an international study; among patients receiving trastuzumab deruxtecan, 45.0% were from Europe or Israel, 38.7% were from Asia, and 16.3% were from North America. The percentage of patients with visceral metastasis at baseline was 90%. Liver metastases was a prominent baseline characteristic: 74.6% of patients in the experimental arm had liver metastases. Lung metastases and brain metastases were reported in 29.6% and 5.4% of patients at baseline, respectively.
In terms of efficacy, trastuzumab deruxtecan elicited a superior median progression-free survival at 10.1 months vs 5.4 months with TPC (HR, 0.51; P < .001). Similarly, median OS was significantly longer in the experimental group at 23.9 months vs 17.5 months, respectively (HR, 0.64; P = .0028).
Notably, trastuzumab deruxtecan was associated with fewer grade 3 or greater treatment emergent adverse events (TEAEs) than physician’s choice of treatment. The percentage of patients receiving trastuzumab deruxtecan who experienced a grade 3 or higher TEAE was 52.6% (n = 195) vs 67.4% in the control group (n = 116).
Conversely, more patients receiving the antibody-drug conjugate required a dose discontinuation compared with TCP; 16.2% (n = 60) vs 8.1% (n = 14), respectively. The most common TEAEs which emerged during trastuzumab deruxtecan treatment were nausea (73%), fatigue (48%), and neutropenia (33%). The rates of nausea and fatigue were greater in the experimental arms than control arms; 24% of patients receiving TPC experienced nausea and 42% experienced fatigue. However, less patients receiving trastuzumab deruxtecan experienced neutropenia than their control counterparts (51%).
Investigators used 3 key PRO measures to better understand patient experiences with the study treatments. They leveraged the oncology-specific EORTC QLQ-C30 to measure GHS and QOL, as well as functioning and symptom scales, this assessment analyzed changes from baseline and TDD. The breast cancer-specific EORTC QLQ-BR23 provided insight as to how the treatments influenced patients’ breast cancer-specific symptoms—specifically arm and breast symptoms. The EQ-5D-5L queried patients with generic questions to get a self-rated health status.
The rate of questionnaire compliance was high; 92% of patients filled out the questionnaires at baseline (cycle 1) and 80% of patients filed questionnaires between cycles 2 and 27. Patients were asked to complete these assessments at each of the first 3 cycles. Following cycle 3, they were asked to complete them at every other cycle (cycles 5, 7, 9, etc) for the duration of treatment, as well as to complete them posttreatment at a 40-day follow-up visit, and again at a 3-month follow-up visit.
GHS ranged from 0 to 100. The mean standard deviation at baseline for trastuzumab deruxtecan and TPC were 36.3 ± 21.8 and 37.8± 22.5 at baseline. The mean change from baseline for overall GHS/QOL were within ± 10 and investigators noted they remained stable over the course of treatment with trastuzumab deruxtecan up to 27 cycles and with TPC up to 13 cycles.
“The hazard ratio for time to definitive deterioration favored trastuzumab deruxtecan over TPC for almost all PRO variables of interest, including pain symptoms,” Ueno concluded. “These results suggest trastuzumab deruxtecan treatment delays the deterioration of GHS/QOL and shows a QOL benefit of trastuzumab deruxtecan in patients with hormone receptor–positive, HER2-low metastatic breast cancer.”
Reference
Ueno NT, Jacot W, Yamashita T, et al. Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC). Presented at: ESMO Congress 2022; September 9-13, 2022; Paris, France. Abstract 217O.
Country singer Clint Black got his start in 1989, and had his biggest hits then — songs such as “Killin’ Time” and “A Better Man.” He has kept busy ever since, and these days juggles two different rounds of concert tours a year, including an appearance Thursday at the Knox Memorial Theater in Mount Vernon. Some of his shows are part of the “Mostly Hits and the Mrs.” tour, which also includes his wife, actor and singer Lisa Hartman Black, and his daughter, Lily Pearl Black. The Mount Vernon show is part of his solo tour. It’s intimate and stripped down, rather than an elaborate production. “I roll up my sleeves. That’s my wardrobe change,” Black, 60, said, speaking by phone from his home in Nashville, Tennessee. In addition to singing, Black will be playing guitar and harmonica. He will be accompanied by the guitar player and bassist who have been with him from the beginning, as well as a “great drummer,” a “fantastic keyboardist” and “a guy who plays fiddle, dobro, lap steel and guitar.” Fall Arts & Entertainment:Greater Columbus concerts, comedy shows, theater and more “We have several arrangements where the band really gets to show off,” Black said. “And in the more intimate venues, I talk a little more, usually to get a laugh. We have a lot of laughs in the show.” Black is hands-on in crafting both his music and the show. Most of the numbers in the show are performed in front of video backdrops created by the singer himself. “Back in ’94 I started directing my music videos. I learned a lot over the years from great video producers. I would always come up with a treatment, and my producer would budget it out and say, Yeah, that’ll cost you a million dollars. I had to learn how to cut back and make affordable videos. So I bought a camera and I started to shoot stuff. But I wasn’t an editor until I started doing these stage videos. I hired a couple of guys who would come over and tutor me in how to use the software. I’ve learned a lot in the last three or four years. I could hire people to do that stuff, but then I’d just be coming around looking over their shoulder and saying, ‘Is that too much fire?’ ‘What about the rain?’ I can’t help it. I just love the creative stuff.” Besides making videos during the COVID lockdown, Black also put out a new album, 2020’s “Out of Sane.” In 2021, he began hosting a talk show on country music television network Circle. “Talking in Circles” features lengthy interviews with stars such as Vince Gill, Darius Rucker, Gary LeVox, Joe Bonamassa, Amy Grant, Brad Paisley and many more. He has just finished recording the third season of the show. “The network has been really encouraging about it,” he said. “I can go into the weeds and talk about anything that I would want to talk about with Joe Bonamassa or Dennis Quaid or whoever the guest is. There’s no pressure to be like any other talk show. People who have been on the show, who may have been an acquaintance, or who maybe I met them once briefly, we’ve become friends. And talking to other songwriters about how they do it just gives me another way of looking at songwriting. There are so many ways to have a career, especially now.” Broadway in Columbus:2022-23 season will include 5 shows new to Columbus In his spare time, he also started a coffee business, with the aim of selling freshly ground coffee online. “A friend of mine would help me to get some coffee together and send out to family and friends for Christmas. He said, ‘You’ve got a perfect name to be in the coffee business.’ He’s thinking ‘Clint Black Coffee.’ (Black finally settled on Clint Black Cowboy Coffee as a name.) I have a mom and pop that we found in Texas who roast this for me as we go. So it’s probably three weeks since it was roasted when you get it. I like to be able to squeeze the bag and have it smell like it was just roasted.” In comparison with all the COVID projects, being back on the road touring feels easy. “Now we say,” Black joked, “we have to get out on the road to get some rest.” [email protected] Clint Black will perform at 8 p.m. Thursday, September 15 at the Knox Memorial Theater, 112 E. High St., Mount Vernon. Tickets start at $58. (knoxmemorial.org)
A good Xbox headset should sound great, look good, and last for ages. I’m happy to report that LucidSound’s LS100X headset more or less nails these metrics. In raw quality terms, these cans sit squarely in the middle of the road. But within those parameters, there’s a dang decent set of headphones to discover. Did I mention that they last forever? Well not forever, exactly. But they’re rated for 72 hours of active use. I don’t know how accurate this is, because I haven’t had to charge them yet. I’ve had them for over a week! I just took them out of the box, connected them to my PC, and started using them. Suffice to say, their claims about battery life are well-founded ones. But what about the rest of the specs? Beyond the 72 hours of active battery life, the LS100X can also connect to a device via Bluetooth. This mode allegedly lets you go for 130 hours without needing to recharge. I haven’t had the chance to test this mode out yet, since I still haven’t had to recharge them. There’s also a set of audio controls built into the headset, along with two different mic options. You’ve got mic monitoring to make sure you sound okay, and three different EQ modes to play with. Said modes include first-person shooter, signature sound, and bass boost. They don’t exactly encompass every sound situation, but it’s a good mix for your average gamer. Personally, I’m quite partial to bass boost. Who doesn’t want more oomph built into their music and/or game sound? I didn’t notice a gigantic difference on PC, but other devices (smartphone, Xbox) were a different story. I didn’t spend much time with first person shooter mode, but it’s nice that they thought to include it at all. It took a little time to get used to the built-in audio controls, especially the chat/game volume knobs. They’re disguised as part of the ear pieces, and they continuously baffled me. Turning the volume up or down is different for chat and game sound, something I had to discover the hard way. You eventually figure it out, but it made for a fairly awkward play session with my friends. Other features, like the power and mute buttons, feel a lot more intuitive. Wearing these headphones all day feels pretty decent, all things considered. The headset is super light, which is essential for long-term comfort. My giant ears make any over-the-ear models a tough sell, but the LS100X makes a strong case. As long as you’re not trying to get through an entire work shift, you likely won’t even notice that they’re on. Even then, the level of discomfort (for me at least) was pretty mild. Again, mine is something of an edge case. Having made some serious audiophile purchases in my life, I know what a difference cost and quality can make. This set isn’t gonna blow any doors down, but that’s okay! Quality-wise, you are absolutely getting your money’s worth with the LS100X. If I’m playing games or getting through a whole shift at work, clean mid-range sound is all I need. The microphone isn’t anything to write home about, but it gets the job done. Just don’t try and record any kind of voice work with it. If you’re looking for a good Xbox headset, you wanna check out the LS100X. The sound is clear, the design is slick, and the battery is awesome. Not only that, but they’re lightweight and versatile enough for all your everyday sound needs. You’re not getting that professional, studio-grade sound here. You won’t kick off your career as a podcast host with these cans, either. But for this price, that’s totally okay. This pair of headphones from LucidSound is a reliable, utilitarian piece of equipment that will get you through whatever the day may bring. If you’re shopping for something reliable and dependable, with a dang decent sound to boot, check out the LS100X wireless gaming headset. ***A retail version of the product was provided by the manufacturer*** Developer: LucidSound Publisher: LucidSound
Johnson’s keen creative eye and extensive background in sales and talent representation will further Cadence’s mission: to bring bold, moving ideas to life. The U.S. and France-based live action production company Cadence Films welcomes Executive Producer Jenn Johnson to the team. Working closely alongside Founder/EP Lorenzo Ragionieri, Johnson’s keen creative eye and extensive background in sales and talent representation will further Cadence’s mission: to bring bold, moving ideas to life. “I’m beyond excited to add Jenn to our team, and know she’ll push us to make our best work,” said Ragionieri, who co-founded Cadence Films in 2014. “As a fellow entrepreneur, I’m drawn to her self-starting spirit and appetite for growth.” Johnson’s career includes a variety of prominent, high-impact positions, including President/Lead Sales at her own talent representation company, Open Season; Executive Producer and Head of Sales at the New York-based music production company Music and Strategy; and most recently, as a partner at talent representation firm Hustle. There she had the opportunity to work with some of the most respected directors working today, including Michel Gondry, Martin Krejci, Antoine Bardou-Jacquet, Hannah Lux Davis, Drew Kirsch, and The Bobbsey Twins. While at Hustle, Johnson connected with Lorenzo through mutual friends at the talent placement firm ARC. When she dove into the roster, Johnson felt an instinctual pull to Cadence Films, which is driven by a team of best-in-class producers with expertise in advertising, fashion, music videos, and entertainment. Given Jenn’s self-motivated nature and undeniable enthusiasm for making things happen, the pairing was simpatico from the start. “Immediately I had so much excitement and passion for the directors and the company,” said Johnson. “I could see my next five years pretty clearly, building on Cadence’s existing equity and expanding it with my specific background and network.” Alongside her experience in bringing compelling stories to life on-screen, Johnson’s considerable background in sales, including tenures repping for RadicalMedia and B-Reel Films, gives her the tools to nurture rewarding relationships with creative stakeholders. It’s a winning combination that sets her up to approach this next chapter as an Executive Producer and to expand the reach and impact of Cadence’s groundbreaking and stylistically diverse work. Access the world’s largest advertising database. With an intuitive toolset that helps you explore, present and collaborate more effectively. The smartest way to manage, present and pitch your work. “This is a relationships business, and Jenn has the track record and trust of some of the best directors and agencies in the industry,” said Ragionieri. “In a space that gets more crowded by the year, we need someone who will tirelessly champion our work, and elevate our profile. We’re fortunate to have Jenn in that role.” As she comes aboard, Johnson is particularly looking forward to leaning on her 15+ years experience to better serve Cadence Film’s visionaries and support them in making premier work that expands audiences’ understanding of the genre. “I’m looking forward to cultivating fresh opportunities for our filmmakers to make highly creative work,” said Johnson. “Repping certainly taught me how to turn over every rock, follow every lead, and dream big for my client. The chance to do this with a laser-focus on one specific roster is such a rewarding experience and one that I’ve been craving to take on.” Roberts takes creative helm at BBH USA and joins BBH’s Global Board to drive power of creativity across local markets. For Hennessy’s emblematic VSOP cognac, DDB Paris creates a whole new brand platform, launched by an epic film shot by the Oscar-winning director Paolo Sorrentino. Teaming up with Kohler’s internal creative team, the spot features epic visuals, stellar performances, and seamless product integration. The only creative prize to reward campaigns that resonate most with female audiences announces its 2022 winners. See full credits for all work featured and have instant access to the world’s most powerful and comprehensive advertising database. Stay up-to-date with the latest news, insight and inspiration for the creative community. Access the world’s largest advertising database. With an intuitive toolset that helps you explore, present and collaborate more effectively. Custom-built for the advertising industry, with extensive showreel options and powerful streaming software. Upgrade your showreels today. To access full credit, contact, company and people information, you’ll need a Source membership. Click below to find out how to super-charge your shots experience with the world’s most comprehensive advertising database. shots spotlights the world’s most creative advertising every day. Stay up-to-date with the latest news, insight and inspiration for the global creative community.
– Patients treated with omidubicel reported higher health-related quality of life scores during first-year post-transplant as compared to transplantation with umbilical cord blood (UCB) – If approved, Omidubicel is projected to have meaningful improvement in patient outcomes among racial and ethnic minorities by potentially extending access to allogeneic hematopoietic cell transplant (allo-HCT) and reducing time to transplant –Data highlights robust and diverse T cell reconstitution, with significantly higher recent thymic emigrant (RTE) T cells at 1 year, no loss of TCR repertoire diversity, providing mechanistic rationale for lower viral and overall infection rates observed in patients transplanted with omidubicel BOSTON, September 12, 2022–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the presentation of data supporting the potential of omidubicel for the treatment of patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant at the 2022 Cord Blood Connect Meeting, being held in South Beach, Florida. "We continue to be encouraged by the growing body of evidence supporting the improved outcomes and lower infection rates seen in patients treated with omidubicel as well as the superior health-related quality of life scores compared to transplantation with UCB. We also demonstrated the potential role for omidubicel to address the unmet need for patients who are currently eligible for transplant, but cannot find a match," said Julian Adams, chief executive officer of Gamida Cell. "Our omidubicel BLA was accepted by the FDA and granted priority review with a PDUFA date of January 30, 2023, which we believe further underscores the unmet need for patients with blood cancers in need of a stem cell transplant." Gamida Cell presented a poster titled "Health-Related Quality of Life (HRQL) Following Transplantation with Omidubicel Versus Umbilical Cord Blood (UCB) in Patients with Hematological Malignancies: Results from a Phase III Randomized, Multicenter Study," which included an analysis of 75 patients to evaluate changes in HRQL measures between the two study arms. Outcomes evaluated included Functional Assessment of Cancer Therapy General (FACT-G) domain scores for physical, social/family, functional and emotional well-being, and EQ-5D-3L index scores at days 42, 100, 180 and 365 post-transplant. During the first-year post-transplant, patients receiving omidubicel had numerically superior average FACT-G domain and EQ-5D-3L index scores compared to UCB, with mean differences across time points ranging from 1.4-3.1 for physical well-being, 0-1.3 for social/family well-being, 0.5-1.4 for emotional well-being, 1.6-3.2 for functional well-being, and 0.03-0.09 for the EQ-5D-3L index score. The data suggest meaningfully greater preservation or improvement of important HRQL domains in patients treated with omidubicel compared to UCB. Learn more Gamida Cell also presented a poster titled "Projected Impact of Omidubicel on Racial and Ethnic Disparities in Allogeneic Hematopoietic Cell Transplant Access and Outcomes for Patients with Hematologic Malignancies in the US," which featured an analysis of projected impact of allogeneic hematopoietic cell transplant (allo-HCT) access and clinical outcomes in a hypothetical population of 10,000 allo-HCT-eligible patients with hematologic malignancies lacking an HLA-matched related donor. Assuming 20% omidubicel use, the proportion of patients receiving allo-HCT increased by 71% in Black, 43% in Asian, 30% in Hispanic, and 5% in white patients. The model suggests that access to omidubicel, upon approval, is projected to decrease time to allo-HCT and improve patient outcomes, with the greatest improvements among the racial and ethnic groups underserved by the current standard of care. Learn more In a poster titled "Hematopoietic Stem Cell Transplantation (HSCT) with Omidubicel Leads to Robust Recovery and Diversity of T cells" patients treated with omidubicel were found to have robust and diverse T cell constitution. In an analysis of the T-cell development of 37 patients, patients transplanted with omidubicel demonstrated higher numbers of Recent Thymic Emigrants (RTEs) in peripheral blood at one year post transplant compared to transplantation with UCB, which suggest faster thymopoiesis and provide mechanistic rational for the lower infection rates and improved outcomes in these patients. Learn more All three posters were made available beginning Saturday, September 10, 2022, 6:15-7:45 p.m. ET, during the 2022 Cord Blood Connect Meeting. About Omidubicel Omidubicel is an advanced cell therapy candidate developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant for patients with blood cancers. Omidubicel demonstrated a statistically significant reduction in time to neutrophil engraftment in comparison to standard umbilical cord blood in an international, multi-center, randomized Phase 3 study (NCT0273029) in patients with hematologic malignancies undergoing allogeneic bone marrow transplant. The Phase 3 study also showed reduced time to platelet engraftment, reduced infections and fewer days of hospitalization. One-year post-transplant data showed sustained clinical benefits with omidubicel as demonstrated by significant reduction in infectious complications as well as reduced non-relapse mortality and no significant increase in relapse rates nor increases in graft-versus-host-disease (GvHD) rates. Omidubicel is the first stem cell transplant donor source to receive Breakthrough Therapy Designation from the FDA and has also received Orphan Drug Designation in the US and EU. Omidubicel is an investigational stem cell therapy candidate, and its safety and efficacy have not been established by the FDA or any other health authority.For more information about omidubicel, please visit https://www.gamida-cell.com. About NAM Technology Our NAM-enabling technology is designed to enhance the number and functionality of targeted cells, enabling us to pursue a curative approach that moves beyond what is possible with existing therapies. Leveraging the unique properties of NAM (nicotinamide), we can expand and metabolically modulate multiple cell types — including stem cells and natural killer cells — with appropriate growth factors to maintain the cells’ active phenotype and enhance potency. Additionally, our NAM technology improves the metabolic fitness of cells, allowing for continued activity throughout the expansion process. About Gamida Cell Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapy candidates with potential to redefine standards of care. These include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx. Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates (including omidubicel), regulatory filings submitted to the FDA (including the potential timing of the FDA’s review of the BLA for omidubicel), commercialization planning efforts, and the potentially life-saving or curative therapeutic and commercial potential of Gamida Cell’s product candidates (including omidubicel), and Gamida Cell’s expectations for the expected clinical development milestones set forth herein. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on August 15, 2022, as amended, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements. 1CIBMTR 2019 – allogeneic transplants in patients 12+ years with hematological malignancies. 2Gamida Cell market research View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005342/en/ Contacts For investors: Courtney Turiano Stern Investor Relations, Inc. [email protected] 1-212-362-1200 For media: Heather DiVecchia Director, Investor Relations and Corporate Communications [email protected] 1-617-892-9083 Related Quotes Amylyx Pharmaceuticals has just one drug in its pipeline — but it's for ALS, and the available treatments for that disease leave much to be desired. Cancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. On Sunday, Clovis reported that Rubraca tested very well as a monotherapy for ovarian cancer in the initial part of a phase 3 trial. All told, 538 women suffering from high-grade ovarian, fallopian tube, or primary peritoneal cancer took part in the trial. New data from the first of a new type of cancer drug suggest its benefits and limitations, while leaving room for other candidates seeking to enter the lucrative market. Amgen lung-cancer pill Lumakras beat out a common chemotherapy in a late-stage study, helping patients survive without their tumors getting worse, though it failed to prove that it reduced overall deaths, the company said. The Food and Drug Administration conditionally approved Lumakras last year based on encouraging early-stage study data but required Amgen to conduct a confirmatory study, which the company reported Sunday. Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia. Good news from the Food and Drug Administration (FDA) can send biotech stocks into the stratosphere. Patrick Bafuma (Mirati Therapeutics): One company that has to be champing at the bit to get FDA approval is Mirati Therapeutics, with its lead drug adagrasib. The biotech sector, like most sections of the market, took a sound beating in the year’s first half. Recently, however, the segment’s performance has improved, and that has helped the NASDAQ Biotechnology Index (NBI) pull ahead of the NASDAQ (Up 13% over the past 3 months vs. the NASDAQ’s 3%). The Oppenheimer biotech team thinks there’s a simple explanation for this: “We believe that much of the recent outperformance has been driven by SMID caps, of which many have risen admirably in the past fe Weight-loss and nutrition companies have lost half or more of their value in the past year despite expectations of a postpandemic boom. FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population. Long-term care in residential facilities like nursing homes is a financial challenge for many. When dealing with a loved one who is disabled, elderly or ill, families often try every other kind of long-term care facility first. Because nursing homes … Continue reading → The post Nursing Home Costs: How You Can Cover Them appeared first on SmartAsset Blog. Late Friday, Bristol Myers Squibb (ticker: BMY) announced that the Food and Drug Administration had approved its oral plaque psoriasis treatment deucravacitinib, which will be marketed under the name Sotyktu. More surprising than the approval was the FDA’s decision not to require a so-called “black-boxed warning” on the drug’s label, which the agency uses when a drug carries significant safety risks. Investors had been concerned that similarities between TYK2 inhibitors and another class of drugs, known as Janus kinase inhibitors, which have been the subject of significant FDA safety concerns, would lead the agency to put a black box on Sotyktu. An analyst had a fresh new take on the company's prospects, and it wasn't all that positive. "We believe Sotyktu is a breakthrough in the treatment of patients suffering from moderate-to-severe plaque psoriasis," said Bristol Myers' chief medical officer Samit Hirawat. The things to remember about dementia are that it is absolutely horrible for you and everyone around you; it’s a high probability; and when it comes to fighting it or avoiding it you are pretty much on your own. Alzheimer’s disease and related dementias are currently killing 6.5 million people in the United States and devastating the lives of many times that when you count the patients’ friends and family. The National Institutes of Health reckons this number is likely to double in the next four decades. The death of England’s longest-reigning monarch, Queen Elizabeth II, has stirred up debates about colonialism and the ways the British monarchy has, and continues to do harm. Hundreds of clinics specializing in ketamine treatment for depression and other mood disorders have popped up in the U.S. in recent years. WSJ visits one clinic, Nushama, to learn why some entrepreneurs are betting that demand for ketamine will continue to rise. Photo illustration: Laura Kammermann/WSJ The 35-year-old actress and activist discusses her thoughts on abortion rights. U.S. known cases of COVID are continuing to ease and now stand at their lowest level since early May, although the true tally is likely higher given how many people are testing at home, where the data are not being collected. Initial illness and long COVID have dealt a significant blow to employers—but they’re far from the only issues COVID is creating in the workforce. Hospitals and nursing homes are stressed, say officials. “It almost makes the serious observer of labor relations wonder whether a more massive set of work stoppages are on the horizon,” one expert told Fortune.
Advertisement Supported by Renters When Stanley Brown heard about a recording studio for rent in Manhattan, he immediately took the lease — and landed a luxury apartment just across the river. Send any friend a story As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share. By Marian Bull Since moving to Weehawken, N.J., last fall, Stanley Brown has developed a nightly habit: He works long hours at the recording studio he runs in Midtown Manhattan, and usually takes an Uber home at 2 or 3 in the morning. When he arrives at his apartment building, which sits along the Hudson River with an unfettered view of Manhattan, he takes a quiet walk along the riverfront to process his day. “I take that walk religiously,” said Mr. Brown, who lives alone. “I have conversations with the city at night. I want to see what it is that I’m buying into, or what I’m building there. It’s time to think about what’s happening and what’s coming tomorrow.” Mr. Brown, 54, has been working in the music industry since he was in his early 20s. He grew up in Bedford-Stuyvesant, Brooklyn, where he played drums and keyboard in church. In his 20s, he met the members of the hip-hop group Run-DMC and began playing keyboard for them. (You can see him in the music video for “Pause,” decked out in the group’s signature rope chains and playing a solo on the keytar.) Soon, mentors like Jam Master Jay and the producer Hiriam Hicks taught him the ins and outs of production. Since then, he has written and produced for a range of R&B and gospel acts. He has worked with artists, including Salt-N-Pepa, Dru Hill and Michelle Williams from Destiny’s Child. He also served as senior director of artists and repertoire for RCA Inspiration, a label under Sony Music, and recently signed a distribution deal with Roc Nation. In 2004, Mr. Brown purchased a two-bedroom house in North Hills, N.Y. He built a recording studio, complete with a vocal booth, in his basement, where musicians and other producers would often visit from New York City. But those trips from the city usually meant a two-hour drive back after a recording session. Last year, when the pandemic heated up the real estate market on Long Island, Mr. Brown realized that he could get a good price for his house, and he set his sights on Stroudsburg, Pa. He had two good friends who lived in a gated community there, where he figured he could build out a house with a recording studio and host songwriting camps. But there are no trains that make for an easy commute between New York City and Stroudsburg. Mr. Brown’s friend, the producer Rodney (Darkchild) Jerkins, pointed out the holes in his plan. “He was like, ‘You’re going to be up there by yourself,’” Mr. Brown remembers. “‘Nobody’s coming to work up there.’” As doubt set in, a new opportunity materialized. A friend called to let Mr. Brown know that a recording studio in Manhattan had opened up: Did he want to take the lease? The answer was an obvious, immediate yes. $3,500 | Weehawken, New Jersey Occupation: Music producer His weekend hobby: “I’m a motorcycle guy. I ride bikes really hard. But it’s always on open highways, so it’s safer. I’ll ride with my friends to Jones Beach or the Hamptons. [Interstate] 495, at the right time of day, is wide open.” On taking days off: “I have no problem working weekends, but I don’t like to kill my engineers. So I give them the weekends off. Sundays I’m working, because I’m at my church in Jamaica, Queens. I run the music department. I’ve been there for 21 years.” For Mr. Brown, having a studio “is like water to a fish — I need it to exist,” he said, laughing at his accidental rhyme. “Music is all I know. It’s all I’ve ever done. And if I have a studio, I can always write, I can always play music, I can always play with other artists.” A plan emerged: He would use the money from the sale of his house to invest in the Manhattan studio, which first began as a few rooms and quickly expanded to the whole floor as Mr. Brown created suites for some of the producers who worked with him. “Now we can just create around the clock, and we don’t have to share the space with strangers — you can keep up the energy,” he explained. With the Long Island house sold and the Pennsylvania plan nixed, Mr. Brown began looking for rentals. He had lived in Edgewater, N.J., at the turn of the millennium and began looking along the waterfront in nearby Weehawken. The second building he looked at, a waterfront property owned by Veris Residential that was a stone’s throw away from the Port Imperial ferry terminal, immediately felt right. “The energy was great,” Mr. Brown said. “Walking in, it felt like a hotel. I liked that it was new. And the view played a big factor.” He moved into a $3,500-a-month, one-bedroom apartment there last October, after putting nearly half of his belongings in storage. He will be moving to a two-bedroom, with a wraparound balcony, in the building this fall. When he’s not at the Manhattan studio, he is often on his building’s roof deck, drinking his morning coffee and taking a few calls before heading into the city. The deck and pool area make the place feel like a luxury hotel: “It’s like I get to have a staycation every day at home,” Mr. Brown said. The building also gives him an enviable commute. When he sees the ferry approaching from the floor-to-ceiling windows in his apartment, he knows he has eight minutes to get on. From there, it’s just six minutes to Manhattan, and a brief shuttle takes him a few blocks from his studio. For someone who works long hours, this sort of ease is a luxury. “It just makes me feel good about what I do, where I am,” Mr. Brown said. As it did for so many people, the pandemic offered him an opportunity to prioritize what mattered and discard the rest. Being in control of his living space and his time allows him to focus his creative energy toward the work that sustains him and that has defined his life, he said. The studio is a dream come true, but an expensive one. “I gotta pay for it, so I’m there every day working and writing, constantly finding new writers and engineers to keep it going,” Mr. Brown said. “It’s an investment. But at this point, if I’m going to roll the dice and bet, I’m going to bet on me. Because I have no intentions of losing.” For weekly email updates on residential real estate news, sign up here. Advertisement
This slideshow requires JavaScript. Stages in Miami and Fort Lauderdale will glitter with stars from all corners of the operatic firmament in a grand season filled with romance, ruses, and rebellion. The 81st Season begins with a delightful valentine to Miami’s vibrant international culture, a Spanish-language production of Domenico Cimarosa’s family comedy, El matrimonio secreto (The Secret Marriage). Specially commissioned by FGO general director and CEO Susan T. Danis, the exclusive Spanish translation and 1980s Miami Beach location conceived by Puerto Rican creative Crystal Manich celebrate Miami’s Caribbean, Latin, and South American diaspora. FGO’s prestigious Studio Artists are widely featured in the ensemble cast. In the role of Carolina, who has naughtily married behind her father’s back, Metropolitan Opera soprano Vanessa Bercerra makes house debut. Of Peruvian and Mexican-American descent, this rising star is enjoying a season packed with appearances across the U.S. Second-year Studio Artist Page Michels, fresh from a concert at the Aspen Music Festival, will assume the role for Sunday matinee. Miami soprano and FGO favorite Catalina Cuervo returns in the role of the witty oldest daughter, Elisetta. Cuervo, known as “The Fiery Soprano,” last appeared in FGO’s 2022 Zarzuela concert, and to great acclaim in the title role of 2019’s Frida. First-year Studio Artist and native of Wesley Chapel, FL, soprano Ashley Shalna, will make her FGO debut as Elisetta in the Sunday matinee performance. The role of Fidalma, who has her own designs on her niece’s secret husband, will be taken by first-year Studio Artist, mezzo-soprano Erin Alford, at the Sunday matinee. First-year Studio Artist, tenor Joseph McBrayer, makes his debut as the lovestruck Paolino, secret husband of Carolina. Successful Cuban hotelier and doting papa Geronimo is played by baritone Phillip Lopez, a first-year Studio Artist who recently premiered Thumbprint by Kamala Sankaram at Chautauqua Opera. The role of the cocky Count Robinson is TBD. El matrimonio secreto will be directed by Elena Araoz and conducted by Cuban conductor and founder/music director of Florida Chamber Orchestra, Marlene Urbay. It is a new production by FGO, conceived by Crystal Manich, with set design by Lindsay Fuori, costumes by FGO’s own Darío Almirón, and lighting by Stevie Agnew. The production runs from Nov. 12-15 at the Adrienne Arsht Center for the Performing Arts. Puccini’s comic gem Gianni Schicchi returns to the FGO stage for the first time since 1953. The darkly comic tale of a toxic family who tries to circumvent their late patriarch’s will pairs with Michael Ching’s equally clever contemporary sequel, Buoso’s Ghost, which picks up at the moment Schicchi ends. International baritone Franco Pomponi returns to lead the casts of both operas as the wily lawyer Schicchi, after his triumphant 2017 appearance in the title role of Eugene Onegin. Miami favorite, the venerable Metropolitan Opera mezzo-soprano Robynne Redmon, returns in the role of querulous Aunt Zita, having last graced FGO’s stage as Madame Larina in Eugene Onegin. Once again, FGO’s Studio Artists provide the backbone of the operas, with second-year tenor Charles Calotta and soprano Page Michels as the worried young lovers Rinuccio and Lauretta, Ashley Shalna as Nella, Erin Alford as La Ciesca, Joseph McBrayer as Gherardo, and Philip Lopez as Betto. Audiences will enjoy the rare opportunity to hear a composer conduct his own opera, as Michael Ching takes the stand for both one-acts. Ching served on the FGO music staff for several years at the beginning of his impressive career: first as music assistant, then music administrator, and finally, chorus master. International stage and film director Mo Zhou returns to stage the Puccini comedies, having last overseen 2019’s critically acclaimed Don Giovanni. The double bill runs Jan. 28-31, 2023 at the Adrienne Arsht Center for the Performing Arts in Miami. A fiery tale of love, loyalty, and sacrifice in Napoleonic Rome, Tosca is one of Puccini’s most beloved scores, and the cast is filled with FGO favorites and the most exciting rising stars. Metropolitan Opera soprano Toni Marie Palmertree follows a time-honored FGO tradition, making her house and role debut as Tosca before taking it to the international stage to which she is quickly ascending. Returning as her lover, Cavaradossi is Miami resident, the Mexican star tenor Arturo Chacón Cruz. He last appeared at FGO as Rodolfo in 2012’s La bohème, opposite Metropolitan Opera star soprano Ailyn Pérez as Mimi. Completing the leading trio is FGO favorite, baritone Todd Thomas, an acclaimed veteran Scarpia whose stunning Rigoletto broke hearts in the 2021-22 season. FGO favorite, bass-baritone Neil Neilson, joins the cast as the Sacristan after his triumphant performance as the Emperor Claudius in last season’s Agrippina. Maestro Gregory Buchalter and stage director Jeffrey Marc Buchman reunite after last season’s acclaimed A Streetcar Named Desire to conduct and direct, respectively. The scenery and costumes are from Sarasota Opera. The opera plays Mar. 18- 21 at the Adrienne Arsht Center for the Performing Arts in Miami. In the final show of the season, FGO revives the beloved Rossini comedy, The Barber of Seville, last seen in 2015. Rising star, South Korean baritone Young-Kwang Yoo, takes on the lovable rascal Figaro. Returning as a guest artist after two years in the Studio Program, mezzo-soprano Stephanie Doche brings her brilliant coloratura and charming stage presence to the clever ward Rosina. International tenor, Michele Angelini, plays her suitor, the Count Almaviva. He returns to FGO for the first time since 2013, when he appeared opposite Metropolitan Opera soprano Rachel Gilmore as Elvino in La Sonnambula. The cast is rounded out with former Studio Artist, Brazilian bass-baritone Rafael Porto as Don Basilio, and soprano Susan Neves as Berta. Casting for Dr. Bartolo will be announced at a later date. Stage director and FGO Studio Artist Program manager Matt Cooksey makes his FGO directing debut composer. Maestro Anthony Barrese, artistic director and principal conductor of Opera Southwest who last appeared with FGO in 2018’s critically acclaimed Orfeo ed Eurydice, conducts. The scenery is provided by the New Orleans Opera Association and costumes are from Sarasota Opera. This perennial favorite runs Apr. 29-May 2 at the Adrienne Arsht Center for the Performing Arts in Miami. Tickets for all shows begin at $16 at the Adrienne Arsht Center for the Performing Arts and are available at fgo.org. To see more #Miaminews from #Aventura to #Coralgables to #SouthMiami, #Pinecrest, #Palmetto Bay and #Cutler Bay and all throughout #Miamidadecounty go to: www.communitynewspapers.com Connect To Your Customers & Grow Your Business
The name Satheerth Kunneth might not ring a bell but if you follow today’s music scene, you would be familiar with the name DJ Shadow Dubai. As soon as Kunneth realized he wanted to make a career out of music, he adopted the stage name DJ Shadow Dubai. Apart from performing all over the world, he has several popular tracks to his credit as a music producer. Some of his chartbusting songs have been ‘Casanova’ and ‘Slowly Slowly’. In this interview, DJ Shadow Dubai talks about his journey in the music industry, collaborating with the likes of Pitbull, doing Bollywood music, upcoming projects and more. One of your recent hits has been ‘Casanova’ on which you collaborated with Yo Yo Honey Singh. Working with Yo Yo Honey Singh was a dream come true. He is a legend and has inspired so many of us. He is not just a rapper but a music producer and a composer as well. I learnt a lot while working with him. It was a lot of fun creating a party song like ‘Casanova’. You had stated in an interview that Bollywood is the next big destination for you. Do you plan to compose or produce music for films? I started off as a music producer. I was doing a lot of remixes and I realized a lot of remixes were happening in Bollywood as well. There came a time when I felt the urge to create original music. If I get the right opportunities, I would love to compose and produce music for films. You have worked on many popular tracks over the years. One of your most loved tracks has been ‘Slowly Slowly’ on which you collaborated with Pitbull and Guru Randhawa. What are your memories of working on this particular project? I have a lot of wonderful memories of working on ‘Slowly Slowly’. We worked on this track for close to nine months. We flew to the United States multiple times and visited Miami frequently while working on it. There is one particular incident which I can never forget. The day we finished shooting the video, Pitbull came up to me and said, “Thank you Shadow for having me on this project.” That made me realize how humble he is as a person. That’s the reason why he is the legend he is. There was great energy on the sets. Guru and I have been friends for a long time. Collaborating with him on this track was a wonderful experience. While you have worked with several music labels, you have also released a lot of music independently. When you release a song independently, you have the freedom to do a lot of things your way. When you work with a label, you are working with individuals who have a lot of experience releasing, distributing and marketing music. It is great to collaborate with established labels as well. You have to know what feedback you should take and what you should keep aside. I enjoy both the processes. Why did you choose DJ Shadow Dubai as your stage name? I wish there was an interesting story behind this (laughs). I was a very shy kid in school. When I thought of becoming a DJ, I thought of having a stage name. At that time, it was very cool for artists in India to use English names. I thought my name should represent my alter ego. It should be my shadow. That’s how the name DJ Shadow Dubai came about. While I was still shy, I would transform into a different person while performing as a DJ. Is there any artist you wish to collaborate with in the near future? I have a wishlist and it’s quite long. Ever since I got into music production, I have been wanting to work with a lot of artists. In the Indian music scene, Arijit Singh is somebody I have been wanting to work with for the longest time. He has had a big influence on my musical journey. What are you doing next? I am very excited about the next track I will be releasing. I have collaborated with American singer – songwriter Jason Derulo on it. The track has got a very different vibe to it. What’s interesting is that Jason has sung a couple of lines in Hindi. The entire track will be a huge surprise for his fans. It has the potential to become a global anthem.
Joe Hernandez Disenchanted cast members Patrick Dempsey, James Marsden, Idina Menzel, Gabriella Baldacchino, Yvette Nicole Brown, Jayma Mays, Maya Rudolph and Amy Adams appear onstage Friday during the D23 Expo 2022 in Anaheim, Calif. Jesse Grant/Getty Images for Disney hide caption Disenchanted cast members Patrick Dempsey, James Marsden, Idina Menzel, Gabriella Baldacchino, Yvette Nicole Brown, Jayma Mays, Maya Rudolph and Amy Adams appear onstage Friday during the D23 Expo 2022 in Anaheim, Calif. It’s been a buzzy few days at Disney’s D23 Expo. Among the many announcements about upcoming projects from the media giant were two new trailers for popular film franchises. The first, Disenchanted, is the follow-up to 2007’s Enchanted, which saw Amy Adams play an agreeable but naive princess hopeful dropped from the fictional land of Andalasia into present-day New York City. Adams returns for the sequel — along with fellow original cast members Patrick Dempsey, Idina Menzel and others — in which she moves to the suburbs but discovers that “her happily ever after hasn’t been so easy to find.” Nothing stays enchanted forever.#Disenchanted, an Original movie, starts streaming November 24 on @DisneyPlus. pic.twitter.com/JXSTfLeXBy Disenchanted will stream on Disney+ starting Nov. 24. Disney is also whetting fans’ appetites with a teaser for its live-action adaptation of The Little Mermaid, the animated classic that hit theaters in 1989. The trailer gives a brief look at star Halle Bailey playing the lead role of Ariel. Out of the sea, wish I could be… part of that world.
Disney's The Little Mermaid is coming to theaters May 26, 2023. pic.twitter.com/lUw5BmYRK5 Melissa McCarthy co-stars as Ursula, Javier Bardem plays Triton, and Alan Menken and Lin-Manuel Miranda have written four new songs for the film. The Little Mermaid comes to theaters on May 26, 2023. Michael Smith, a professor of information technology and marketing at Carnegie Mellon University, said the company’s investment in Disney+ means it can choose to give one movie a streaming debut and the other a theatrical release. Smith said that strategy allows Disney to put out projects that may not have the mass-market appeal to attract audiences to the cinema. “That’s just fine for some movies, say Little Mermaid, that have the built-in name recognition and mass-market appeal you need to get people into the theater on the opening weekend. But it doesn’t work for every movie,” Smith told NPR. “With a streaming release, Disney can use their subscriber data to target [Disenchanted] to the right initial audience (Amy Adams fans, non-traditional fairy-tale stories, Adam Shankman’s directing style), and then give the movie time to breathe on the platform so people can discover it through word of mouth (which is the way many people discovered Ted Lasso on AppleTV),” he wrote. Sponsor Message Become an NPR sponsor
Kosine is one-half of the production duo Da Internz. Published on By Apple Music has launched a new Essential Album radio episode celebrating 15 years of Kanye West’s classic album Graduation, which was released on September 11, 2007. The show is hosted by Kosine, who is one-half of celebrated production duo Da Internz. “The album is all about challenging what it means to graduate from school versus the streets…to achieve. Because on this day, ‘we become legendary.’” Kosine examines how Kanye’s childhood was more suburban that spent on the streets yet West had a relentless hustle. “At a young age he displayed a love of music, a fondness that would become a fixation,” Kosine adds. “He would attend Chicago State University then drop out to focus full-time on his developing craft. Ain’t no Plan B.”
Kosine also dives into Kanye’s brilliant eye as a songwriter and producer. “He wrote and arranged and explored the intricacies of sampling and production. Yet Ye aspired most of all to be behind the mic himself. And so he kept hustling, first by making beats, but then by making records. Because guess what? Beats don’t go No.1 on the Hot 100 charts. Songs do.” Kosine recruited Beastie Boys legend Mike D to examine Kanye’s power. He says, “I was a fan of his right away from his productions. He brought something to the production game I hadn’t heard before. The sped-up samples and aggressive beats. He had this backpack rap style with a pop sensibility.” Kosine then examines how Kanye’s relationship with Jay-Z shaped him as a producer and artist. The Graduation artwork, a striking anime image by Japanese artist Takashi Murakami featuring a Kanye West-like bear being propelled skywards, serves as an apt analogy for the stratospheric creative ambitions of Kanye’s third album. Following the success of 2005’s Late Registration, he’d toured in support of U2 in an effort to broaden his fanbase. Watching the Irish megastars playing to packed arenas inspired Kanye to create an album that would invest rap with rock and pop dynamics, penning simplified lyrics that would better translate to large crowds. Gone were the soul samples and grand orchestration that had dominated his first two albums. For Graduation, Kanye tapped into the stadium rock of the likes of The Killers, Radiohead, and Keane, while an eclectic selection of samples further broadened the album’s diverse sound. Lead single “Stronger” hinted at what would follow, its revolutionary hip-hop template combining a sample of Daft Punk’s “Harder, Better, Faster, Stronger” welded to heavy metallic beats and hair-rock synths. The song proved a huge hit, especially in the UK, where it became Kanye’s first No.1 single. Listen to Apple Music’s Essentials episode on Graduation. Your email address will not be published. Required fields are marked *